MTOR and glioblastoma: In addition to direct antitumor activity, there is further evidence supporting the efficacy of the mTOR blockade in GBM: in isocitrate dehydrogenase (IDH)-wildtype glioblastoma (GBM), PI3K/mTOR is one of the frequently altered molecular pathways, due to the loss of the tumor suppressor phosphatase and tensin homolog [7,8].